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et al.: Randi Altmark, RN, BSN, CNOR

Changing Lives Through Research

On the Job
Randi Altmark, RN, BSN, CNOR
Through the American College of Surgeons
National Surgical Quality Improvement
Program (ACS NSQIP®), the Department
of Surgery continually searches for ways
to further improve the quality of
surgical care delivered to our patients.
As our NSQIP Surgical Clinical Nurse
Reviewer, Randi Altmark plays a pivotal
role in collecting and maintaining the
data necessary to identify and act on
opportunities for improvement.
When she returned to Jefferson to assume
this role in 2006, Altmark brought more
than 20 years of experience in nursing –
including seven years as a Jefferson OR
nurse and experience as an OR manager
and business manager for surgical
services as well as labor and delivery.

Dr. Shruti Lal, PhD is conducting groundbreaking research on how the HuR protein
regulates cell growth in pancreatic cancer cells.

Plant Biologist Shruti Lal,
PhD, Identifies New Molecule
That Could Prove Key in
Treating Pancreatic Cancer
When Shruti Lal, PhD, joined the
Division of Surgical Research as a
post-doctoral researcher, she brought
an intriguing blend of experience to
the lab.
A veritable Renaissance woman,
Dr. Lal has earned Master’s degrees
in both Botany and Computational
Biosciences. She holds a two-year
diploma in e-commerce and web
design, and has more than six years
of professional experience in software
development, teaching and research.
She also studied Molecular Biology
techniques at the U.S. Department of
Energy’s Joint Genome Institute and
explored microarray printing, scanning
and hybridization at the University of
California, San Francisco.
As a doctoral student at the University
of California, Riverside, Dr. Lal studied
the molecular mechanism that controls
floral specification in the model plant
Arabidopsis thaliana. Her goal was to
establish the gene regulatory networks
(GRNs) that promote flowering and
floral specification in Arabidopsis.
She applied a variety of approaches –
including molecular, genomic and
bioinformatics – to understand these
networks.
As Dr. Lal explains, plants and animals
have a fundamental difference.
While human children are essentially

miniature versions of human adults, a
young plant is not simply a mini-model
of an adult plant: “The plant at juvenile
stage has leaves and stems, but upon
transition to adult stage it initiates new
organs such as flowers,” Dr. Lal says.
“My doctoral research was focused on
understanding what changes occur that
drive plants to start producing flowers.”
Despite opportunities to work in the
field of plant research, Dr. Lal was eager
to apply her skills to studying human
disease. That desire led her to Jonathan
Brody, PhD, Director of the Division
of Surgical Research, who offered
Dr. Lal a position focusing on cancer
research. While it might not seem like
the most logical career move, Dr. Brody
explains, “Dr. Lal brings an intense
dedication and fresh perspective to my
research team that is invaluable.” From
the outset, he posed two challenging
questions to her: How do pancreatic
cancer cells live with genetic mutations,
and how do they become resistant to
chemotherapies?

Identifying a novel
HuR-regulated molecule

Jefferson scientists previously identified
the RNA binding protein HuR
(Human antigen R) as a key molecule
in pancreatic cancer cells. More than
half of patients with pancreatic cancer
express high cytoplasmic levels of HuR

Altmark maintains Jefferson’s ACS NSQIP
database by abstracting relevant clinical
data from patient charts. With data points
spanning pre-op, intra-op and post-op
variables, the database enables Jefferson
to generate risk-adjusted reports and
trend the quality of surgical care. As a
participant in this program, Jefferson can
benchmark itself against other hospitals
in order to evaluate its own performance
and cultivate best practices. In addition to
maintaining the database, Altmark works
closely with Surgeon Champions Herbert
E. Cohn, MD, Scott Cowan, MD, and
Stacey Milan, MD and other health care
providers to develop and execute process
improvements.

and those patients are more likely to
respond well to the drug gemcitabine
than those with relatively low levels
of HuR. While this knowledge is
important, understanding exactly how
HuR functions in pancreatic cancer
cells is critical. This has been the focus
of Dr. Lal’s research since joining the
Jefferson team in November 2011.

“...if a chemotherapy drug
can be designed to inhibit
the interaction between
HuR and WEE1, pancreatic
cancer cells will be much
more likely to die.”

The NSQIP program enables surgeons,
anesthesiologists, nurses and other
clinicians to view summaries of patient
outcomes based on objective clinical data.
Working with others, they can modify
their practice to provide improved care to
surgical patients. For example, NSQIP data
has been used to help drive improvements
in rates of surgical site infections.
“It’s rewarding to know that my relatively
small but vital contribution can greatly
benefit patients receiving surgical care,”
Altmark says. “And, I enjoy collaborating
with surgeons and clinicians, who all
contribute their expertise and unify
around a common goal of providing the
best-quality care possible for Jefferson
patients.”
“Above all, I’m very grateful to work in
a collaborative environment with people
who recognize that while we’re doing a
great job, we can always do better,”
she concludes.

Through the research, Dr. Lal has
found that removing the HuR protein
impairs WEE1 function and promotes
cell death. Thus, Dr. Lal explains, if a
chemotherapy drug can be designed to
inhibit the interaction between HuR
and WEE1, pancreatic cancer cells will
be much more likely to die.
With her groundbreaking manuscript
currently in review, Dr. Lal’s long-term
goal remains clear: “We want to quickly
get this information from the bench
to the bedside,” she says, noting that
pancreatic cancer deaths are rising at
an alarming rate, while other types of
cancer deaths are steadily declining.
“Our objective is to reverse that trend.”

In that time, Dr. Lal has identified the
mechanism by which HuR regulates
the WEE1 molecule (a gate keeper
of cell growth) when cancer cells are
exposed to certain chemotherapeutic
drugs. “When chemotherapy is used,
pancreatic cancer cells with the HuR
protein incur some damage but protect
themselves by putting themselves on
‘hold,’ and thereby prevent cell death,”
Dr. Lal explains.
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